Last10K.com

La Jolla Pharmaceutical Co (LJPC) SEC Filing 10-Q Quarterly report for the period ending Wednesday, September 30, 2020

La Jolla Pharmaceutical Co

CIK: 920465 Ticker: LJPC
Exhibit 99.1



ljpcpressrelease_image1a25.jpg

La Jolla Pharmaceutical Company Announces Preliminary GIAPREZA™ (Angiotensin II) Net Sales for the Three and Twelve Months Ended December 31, 2019


SAN DIEGO, CA - January 9, 2020 - La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced preliminary GIAPREZA™ (angiotensin II) net sales for the three and twelve months ended December 31, 2019. For the three months ended December 31, 2019, preliminary GIAPREZA net sales were $7.2 million, up 71% from the three months ended December 31, 2018 and up 26% from the three months ended September 30, 2019. Vials of GIAPREZA shipped from distributors to hospitals (hospital demand) grew 74% for the three months ended December 31, 2019 as compared to the three months ended December 31, 2018 and 18% as compared to the three months ended September 30, 2019. For the twelve months ended December 31, 2019, preliminary GIAPREZA net sales were $23.1 million, up 129% from the twelve months ended December 31, 2018. La Jolla announced the commercial availability of GIAPREZA in the U.S. in March 2018.

As of December 31, 2019, La Jolla had approximately $87.8 million in cash and cash equivalents, compared to $104.8 million as of September 30, 2019. Net cash used in operating activities for the three months ended December 31, 2019 was approximately $17.0 million. La Jolla has no debt.

About GIAPREZA

In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA mimics the body’s endogenous regulatory peptide that is central to the renin-angiotensin-aldosterone system to increase blood pressure. Prescribing information for GIAPREZA is available at www.giapreza.com. GIAPREZA is marketed by La Jolla Pharmaceutical Company on behalf of La Jolla Pharma, LLC, its wholly owned subsidiary.

IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

There is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive GIAPREZA. Use concurrent venous thromboembolism (VTE) prophylaxis.

Adverse Reactions

The most common adverse reactions that were reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events.

Drug Interactions

Angiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARB) may reduce response to GIAPREZA.




The following information was filed by La Jolla Pharmaceutical Co (LJPC) on Friday, January 10, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate La Jolla Pharmaceutical Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by La Jolla Pharmaceutical Co.

Continue

Assess how La Jolla Pharmaceutical Co's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

La Jolla Pharmaceutical Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Financial
M & A
Revenue
Other
Filter by Subcategory:
All
Expense
Product
Earnings
Other
Inside La Jolla Pharmaceutical Co's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Cover Page
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Consolidated Statements Of Shareholders' (Deficit) Equity (Unaudited)
Acquisition Of Tetraphase Pharmaceuticals, Inc
Acquisition Of Tetraphase Pharmaceuticals, Inc (Tables)
Acquisition Of Tetraphase Pharmaceuticals, Inc - Summary Of Purchase Price Allocation As Of Acquisition Date (Details)
Acquisition Of Tetraphase Pharmaceuticals, Inc. Additional Information (Details)
Balance Sheet Details
Balance Sheet Details (Tables)
Balance Sheet Details - Additional Information (Details)
Balance Sheet Details - Property Plant And Equipment (Details)
Balance Sheet Details - Schedule Of Intangible Assets, Net (Details)
Balance Sheet Details - Schedule Of Inventory (Details)
Balance Sheet Details - Schedule Of Other Noncurrent Liabilities (Details)
Balance Sheet Details - Summary Of Accrued Expenses (Details)
Basis Of Presentation And Summary Of Significant Accounting Policies
Basis Of Presentation And Summary Of Significant Accounting Policies (Policies)
Basis Of Presentation And Summary Of Significant Accounting Policies (Tables)
Basis Of Presentation And Summary Of Significant Accounting Policies - Additional Information (Details)
Basis Of Presentation And Summary Of Significant Accounting Policies - Schedule Of Concentration Risk (Details)
Business
Business - Additional Information (Details)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Details)
Commitments And Contingencies - Lease Liability Maturity (Details)
Company-Wide Realignment
Company-Wide Realignments - Additional Information (Details)
Deferred Royalty Obligation
Deferred Royalty Obligation - Additional Information (Details)
Equity Incentive Plans
Equity Incentive Plans (Narrative) (Details)
Equity Incentive Plans (Share-Based Compensation Expense) (Details)
Equity Incentive Plans (Stock Option Activity) (Details)
Equity Incentive Plans (Tables)
License Agreements
License Agreements - Additional Information (Details)
Net Loss Per Share
Net Loss Per Share (Details)
Other Income-Related Party - Additional Information (Details)
Other Income???Related Party
Shareholders Deficit (Details)
Shareholders Equity

Material Contracts, Statements, Certifications & more

La Jolla Pharmaceutical Co provided additional information to their SEC Filing as exhibits

Ticker: LJPC
CIK: 920465
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-20-052582
Submitted to the SEC: Mon Nov 09 2020 4:59:07 PM EST
Accepted by the SEC: Mon Nov 09 2020
Period: Wednesday, September 30, 2020
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ljpc/0001564590-20-052582.htm